Mimedx Group, INC

MiMedx Group announced Q2 2026 results with net sales of $64 million, down 35% year-over-year, while simultaneously revealing plans to acquire Sanara MedTech for approximately $350 million.

MiMedx Group, Inc. announced its definitive agreement to acquire Sanara MedTech Inc. for approximately $350 million in a cash and stock transaction, aiming to expand its surgical footprint and regenerative medicine offerings.

MiMedx Group held its 2026 Annual Meeting, re-electing directors, approving executive compensation, and ratifying auditor appointment, alongside a bylaw amendment.

MiMedx Group, Inc. reported a significant decline in first-quarter net sales due to new Medicare reimbursement policies impacting its Wound business, while its Surgical segment showed strong growth.

MiMedx Group is eliminating the COO role and reducing executive salaries as part of a $40 million annual cost-cutting initiative.

MiMedx Group, Inc. announced record operating and financial results for the fourth quarter and full year 2025, alongside a new $100 million share repurchase authorization.

MiMedx Group, Inc. announced its second quarter 2026 financial results, highlighting continued growth in its Surgical segment despite an overall revenue decline driven by its Wound care division.

MiMedx Group, Inc. reported robust third-quarter 2025 results with net sales increasing 35.3% and net income more than doubling year-over-year, driven by strong performance in both Wound and Surgical product portfolios.

MiMedx Group announced a 13.1% increase in net sales for Q2 2025, reaching $98.6 million, but reported a 45.4% decrease in net income due to the absence of prior year's non-recurring benefits and increased operating expenses, while facing potential significant impacts from proposed CMS reimbursement changes.

MiMedx Group, Inc. announced a 4% increase in net sales for the first quarter of 2025, driven by growth in its surgical product line, while maintaining a strong cash position.

MiMedx Group, Inc. announced a 2.9% year-over-year increase in net sales for the third quarter of 2024, reaching $84.1 million, with growth primarily in private office settings and balanced between wound and surgical products.

MiMedx Group, Inc. announced a 7.3% year-over-year increase in net sales for the second quarter of 2024, driven by growth in both wound and surgical product lines.

MiMedx Group, Inc. achieved significant revenue and net income growth in 2025, driven by product expansion, but faces substantial headwinds from new Medicare reimbursement policies effective January 2026.

MiMedx Group, Inc. announces an 8.5% increase in net sales for 2024, driven by commercial execution and new product demand, while addressing Medicare reimbursement uncertainties and focusing on strategic growth initiatives.

MiMedx extends its lease agreement for its Marietta, Georgia facility, files its annual report, and refinances its debt to improve its capital structure.

MiMedx Group Inc. announced its definitive agreement to acquire Sanara MedTech Inc. for $35 per share, a move expected to significantly expand its surgical business and create a leading regenerative medicine company.

MiMedx announced an agreement to acquire Sanara MedTech, aiming to bolster its regenerative medicine offerings and expand its surgical business.

MIMEDX and Sanara MedTech announced a definitive agreement for MIMEDX to acquire Sanara, aiming to create a larger regenerative medicine company in the surgical space.

MiMedx Group, Inc. reported a 35% decrease in Q2 2026 net sales to $64 million, driven by a 61% drop in Wound sales due to Medicare reimbursement changes, while Surgical sales grew 15%. The company also announced the acquisition of Sanara MedTech for approximately $350 million.

MiMedx Group, Inc. announced its definitive agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at approximately $350 million.

Mimedx Group, Inc. Chief Financial Officer Doug Rice reported a transaction involving the withholding of shares for tax payments related to restricted stock units.

MIMEDX Group, Inc. has scheduled its 2025 Annual Meeting of Shareholders for June 18, 2025, where key proposals include the election of nine directors, advisory approval of executive compensation, auditor ratification, and an amendment to the 2016 Equity and Cash Incentive Plan.

MiMedx Group is asking shareholders to approve an amendment to its 2016 Equity and Cash Incentive Plan to increase the number of shares available for issuance by 7,950,000, aiming to attract and retain key talent.

MiMedx Group, Inc. has filed a definitive proxy statement with the SEC.

MiMedx Group will hold its 2024 annual meeting of shareholders virtually on June 5, 2024, to vote on director elections, executive compensation, and the ratification of its independent accounting firm.

Trigran Investments and its principals have reported a 4.2% beneficial ownership stake in MiMedx Group, Inc. as of December 31, 2025.